Treatment for newly diagnosed Ph+ ALL in adults
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment plan for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to see if the combination of drugs can effectively control the leukemia while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a specific type of leukemia called Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
- Your liver, kidneys, heart, and lungs should be working well, unless any problems are caused by the leukemia itself.
- You cannot be pregnant or breastfeeding.
- You cannot have serious heart problems, uncontrolled high blood pressure, or a history of pancreatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
This trial tests a combination of targeted immunotherapy (a drug that helps your immune system fight cancer) plus low-dose chemotherapy for adults newly diagnosed with a specific type of blood cancer called Ph-negative B-ALL. The goal is to see if this approach can work better than standard treatments while being easier on your body.
Hear when a new Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.